Filing Flows › GSK (GSK) › Specialty Medicines revenue
GSK (GSK) Specialty Medicines revenue by quarter
GSK's Specialty Medicines revenue was $3.9B in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 5 quarters it ranged from $3.2B (Q1 2026) to $3.9B (Q3 2026).
| Quarter | Specialty Medicines revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.9B | +3% | +14% |
| Q2 2026 | $3.8B | +17% | +14% |
| Q1 2026 | $3.2B | -5% | — |
| Q3 2025 | $3.4B | +2% | — |
| Q2 2025 | $3.3B | — | — |
Q3 2026 at a glance
GSK, Q3 2026: revenue $8.9B (+4% year over year), operating margin 23.9%, net earnings $1.5B, operating cash flow $3.1B. The chart follows the revenue to costs, profit and cash.
Questions
What is GSK's Specialty Medicines revenue?
GSK's Specialty Medicines revenue was $3.9B in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has GSK's Specialty Medicines revenue changed?
Over the last 5 quarters it ranged from $3.2B (Q1 2026) to $3.9B (Q3 2026).